Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules

Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen

(2020) Yurina Ogawa et al.   CLINICAL CANCER RESEARCH

Development of novel FAP-targeted radiotracers with improved tumor retention

(2019) Anastasia Loktev et al.   JOURNAL OF NUCLEAR MEDICINE

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer

(2019) Tessa P. Sandberg et al.   BMC CANCER

Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

(2019) Micol Eleonora Fiori et al.   Molecular Cancer

Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA

(2019) Mary-Ann Elvina Xavier et al.   NUCLEAR MEDICINE AND BIOLOGY

Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid

(2018) Qingqing Miao et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Fibroblast activation proteins-α suppress tumor immunity by regulating T cells and tumor-associated macrophages

(2018) Chun Mei Hou et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein

(2018) Thomas Lindner et al.   JOURNAL OF NUCLEAR MEDICINE

A new method for tumor imaging by targeting cancer associated fibroblasts

(2018) Anastasia Loktev et al.   JOURNAL OF NUCLEAR MEDICINE

Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics

(2018) Ellen Puré et al.   ONCOGENE

Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis

(2018) Tessa van der Geest et al.   RHEUMATOLOGY

FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers

(2018) Frederik Giesel et al.   JOURNAL OF NUCLEAR MEDICINE

Turning foes to friends: targeting cancer-associated fibroblasts

(2018) Xueman Chen et al.   NATURE REVIEWS DRUG DISCOVERY

Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?

(2017) Lucienne Juillerat-Jeanneret et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein

(2017) Roger Yazbeck et al.   PROTOPLASMA

Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules

(2016) Kristina Westerlund et al.   MOLECULAR PHARMACEUTICS

Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis

(2015) P. Laverman et al.   JOURNAL OF NUCLEAR MEDICINE

Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)

(2015) FUMING ZI et al.   Molecular Medicine Reports

Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging

(2015) Romana Meletta et al.   MOLECULES

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

(2015) Yannick Waumans et al.   Frontiers in Immunology

Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)

(2014) Koen Jansen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis

(2013) Yida Liao et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

(2013) Koen Jansen et al.   ACS Medicinal Chemistry Letters

DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes

(2012) Mathieu Moreau et al.   BIOCONJUGATE CHEMISTRY

Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity

(2012) Oxana Ryabtsova et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Fibroblast Activation Protein in Remodeling Tissues

(2012) M. Jacob et al.   CURRENT MOLECULAR MEDICINE

Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy

(2012) W. N. Brennen et al.   MOLECULAR CANCER THERAPEUTICS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance

(2012) Min Shi   WORLD JOURNAL OF GASTROENTEROLOGY

Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein

(2011) Shu-Jen Chen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

The dipeptidyl peptidase IV family in cancer and cell biology

(2010) Denise M. T. Yu et al.   FEBS Journal

On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

(2008) Beni Wolf et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY